Cholesterol synthesis in the fetal brain is inhibited because activity of DHCR24 (24-dehydrocholesterol reductase) is insufficient, causing concentrations of the precursor desmosterol to increase temporarily to 15-25% of total sterols at birth. We demonstrate that failure of DHCR24 to be adequately upregulated during periods of elevated cholesterol synthesis in the brain results from the presence in its promoter of the repressor element 1 (RE1) nucleotide sequence that binds the RE1-silencing transcription factor (REST) and that REST, generally reduced in neural tissues, uncharacteristically but not without precedent, enhances DHCR24 transcription. DHCR24 and REST mRNA levels are reduced 3- to 4-fold in fetal mouse brain compared to liver (p < 0.001). Chromatin immunoprecipitation assays suggested that REST binds to the human DHCR24 promoter in the vicinity of the predicted human RE1 sequence. Luminescent emission from a human DHCR24 promoter construct with a mutated RE1 sequence was reduced 2-fold compared to output from a reporter with wild-type RE1 (p < 0.005). Silencing REST in HeLa cells resulted in significant reductions of DHCR24 mRNA (2-fold) and DHCR24 protein (4-fold). As expected, relative concentrations of Δ24-cholesterol precursor sterols increased 3- to 4-fold, reflecting the inhibition of DHCR24 enzyme activity. In contrast, mRNA levels of DHCR7 (sterol 7-dehydrocholesterol reductase), a gene essential for cholesterol synthesis lacking an RE1 sequence, and concentrations of HMGR (3-hydroxy-3-methyl-glutaryl-CoA reductase) enzyme protein were both unaffected. Surprisingly, a dominant negative fragment of REST consisting of just the DNA binding domain (about 20% of the protein) and full-length REST enhanced DHCR24 expression equally well. Furthermore, RE1 and the sterol response element (SRE), the respective binding sites for REST and the SRE binding protein (SREBP), are contiguous. These observations led us to hypothesize that REST acts because it is bound in close proximity to SREBP, thus amplifying its ability to upregulate DHCR24. It is likely that modulation of DHCR24 expression by REST persisted in the mammalian genome either because it does no harm or because suppressing metabolically active DHCR24 while providing abundant quantities of the multifunctional sterol desmosterol during neural development proved useful.

Keywords:
Cholesterol, Regulation, Neural tissue, Development, Repressor element 1 sequence, Sterol response element
1.
Spady DK, Dietschy JM: Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat. J Lipid Res 1983;24:303-315.
2.
Chevallier F: Transferts et synthèse du cholesterol chez le rat au course de sa croissance. Biochim Biophys Acta 1964;84:316-339.
3.
Connor WE, Lin DS: Placental transfer of cholesterol-4-C14 into rabbit and guinea pig fetus. J Lipid Res 1967;8:558-564.
4.
Tint GS, Yu H, Shang Q, Xu G, Patel SB: The use of the Dhcr7 knockout mouse to accurately determine the origin of fetal sterols. J Lipid Res 2006;47:1535-1541.
5.
Hinse CH, Shah SN: The desmosterol reductase activity of rat brain during development. J Neurochem 1971;18:1989-1998.
6.
Kritchevsky D, Holmes WL: Occurrence of desmosterol in developing rat brain. Biochem Biophys Res Commun 1962;7:128-131.
7.
Fumagalli R, Paoletti R: The identification and significance of desmosterol in the developing human and animal brain. Life Sci 1963;5:291-295.
8.
Jansen M, Wang W, Greco D, Bellenchi GC, di Porzio U, Brown AJ, Ikonen E: What dictates the accumulation of desmosterol in the developing brain? FASEB J 2013;27:865-870.
9.
Dietschy JM, Turley SD: Cholesterol metabolism in the brain. Curr Opin Lipidol 2001;12:105-112.
10.
Goodrum JF: Cholesterol synthesis is down-regulated during regeneration of peripheral nerve. J Neurochem 1990;54:1709-1715.
11.
Fitzky BU, Moebius FF, Asaoka H, Waage-Baudet H, Xu L, Xu G, Maeda N, Kluckman K, Hiller S, Yu H, Batta AK, Shefer S, Chen T, Salen G, Sulik K, Simoni RD, Ness GC, Glossmann H, Patel SB, Tint GS: 7-Dehydrocholesterol-dependent proteolysis of HMG-CoA reductase suppresses sterol biosynthesis in a mouse model of Smith-Lemli-Opitz/RSH syndrome. J Clin Invest 2001;108:905-915.
12.
Waterham HR, Koster J, Romeijn GJ, Hennekam RC, Vreken P, Andersson HC, FitzPatrick DR, Kelley RI, Wanders RJ: Mutations in the 3β-hydroxysteroid Δ24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. Am J Hum Genet 2001;69:685-694.
13.
Bae SH, Paik YK: Cholesterol biosynthesis from lanosterol: development of a novel assay method and characterization of rat liver microsomal lanosterol Δ24-reductase. Biochem J 1997;326:609-616.
14.
Zerenturk EJ, Sharpe LJ, Ilkonen E, Brown AJ: Desmosterol and DHCR24: unexpected new directions for a terminal step in cholesterol synthesis. Prog Lipid Res 2013;52:666-680.
15.
Chong JA, Tapia-Ramirez J, Kim S, Toledo-Aral JJ, Zheng Y, Boutros MC, Altshuller YM, Frohman MA, Kraner SD, Mandel G: REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell 1995;80:949-957.
16.
Schoenherr CJ, Anderson DJ: Silencing is golden: negative regulation in the control of neuronal gene transcription. Curr Opin Neurobiol 1995;5:566-571.
17.
Schoenherr CJ, Paquette AJ, Anderson DJ: Identification of potential target genes for the neuron-restrictive silencer factor. Proc Natl Acad Sci USA 1996;93:9881-9886.
18.
Wood IC, Belyaev ND, Bruce AW, Jones C, Mistry M, Roopra A, Buckley NJ: Interaction of the repressor element 1-silencing transcription factor (REST) with target genes. J Mol Biol 2003;334:863-874.
19.
Abramovitz L, Shapira T, Ben Dror I, Dror V, Granot L, Rousso T, Landoy E, Blau L, Thiel G, Vardimon L: Dual role of NRSF/REST in activation and repression of the glucocorticoid response. J Biol Chem 2008;283:110-119.
20.
Bessis A, Champtiaux N, Chatelin L, Changeux JP: The neuron-restrictive silencer element: a dual enhancer/silencer crucial for patterned expression of a nicotinic receptor gene in the brain. Proc Natl Acad Sci USA 1997;94:5906-5911.
21.
Kallunki P, Edelman GM, Jones FS: The neural restrictive silencer element can act as both a repressor and enhancer of L1 cell adhesion molecule gene expression during postnatal development. Proc Natl Acad Sci USA 1998;95:3233-3238.
22.
Seth KA, Majzoub JA: Repressor element silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) can act as an enhancer as well as a repressor of corticotropin-releasing hormone gene transcription. J Biol Chem 2001;276:13917-13923.
23.
Yu H, Wessels A, Chen J, Phelps AL, Oatis J, Tint GS, Patel SB: Late gestational lung hypoplasia in a mouse model of the Smith-Lemli-Opitz syndrome. BMC Dev Biol 2004;4:1.
24.
Bruce AW, Donaldson IJ, Wood IC, Yerbury SA, Sadowski MI, Chapman M, Gottgens B, Buckley NJ: Genome-wide analysis of repressor element 1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) target genes. Proc Natl Acad Sci USA 2004;101:10458-10463.
25.
Zerenturk EJ, Sharpe LJ, Brown AJ: Sterols regulate 3β-hydroxysterol Δ24-reductase (DHCR24) via dual sterol regulatory elements: cooperative induction of key enzymes in lipid synthesis by sterol regulatory element binding proteins. Biochim Biophys Acta 2012;1821:1350-1360.
26.
Tseng WC, Lin JW, Wei TY, Fang TY: A novel megaprimed and ligase-free, PCR-based, site-directed mutagenesis method. Anal Biochem 2008;375:376-378.
27.
Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, Frisch M, Bayerlein M, Werner T: MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005;21:2933-2942.
28.
Drzewinska J, Walczak-Drzewiecka A, Ratajewski M: Identification and analysis of the promoter region of the human DHCR24 gene: involvement of DNA methylation and histone acetylation. Mol Biol Rep 2011;38:1091-1101.
29.
Daimiel LA, Fernandez-Suarez ME, Rodriguez-Acebes S, Crespo L, Lasuncion MA, Gomez-Coronado D, Martinez-Botas J: Promoter analysis of the DHCR24 (3β-hydroxysterol Δ24-reductase) gene: characterization of SREBP (sterol-regulatory-element-binding protein)-mediated activation. Biosci Rep 2013;33:57-69.
30.
Tint GS, Salen G: Evidence for the early reduction of the 24,25 double bond in the conversion of lanosterol to cholesterol in cerebrotendinous xanthomatosis. Metabolism 1977;26:721-729.
31.
Tint GS, Irons M, Elias ER, Batta AK, Frieden R, Chen TS, Salen G: Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. N Engl J Med 1994;330:107-113.
32.
Porter FD: Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet 2008;16:535-541.
33.
Andres ME, Burger C, Peral-Rubio MJ, Battaglioli E, Anderson ME, Grimes J, Dallman J, Ballas N, Mandel G: CoREST: a functional corepressor required for regulation of neural-specific gene expression. Proc Natl Acad Sci USA 1999;96:9873-9878.
34.
Lunyak VV, Burgess R, Prefontaine GG, Nelson C, Sze SH, Chenoweth J, Schwartz P, Pevzner PA, Glass C, Mandel G, Rosenfeld MG: Corepressor-dependent silencing of chromosomal regions encoding neuronal genes. Science 2002;298:1747-1752.
35.
Hakimi MA, Bochar DA, Chenoweth J, Lane WS, Mandel G, Shiekhattar R: A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes. Proc Natl Acad Sci USA 2002;99:7420-7425.
36.
Lee MG, Wynder C, Cooch N, Shiekhattar R: An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 2005;437:432-435.
37.
Brown MS, Goldstein JL: A proteolytic pathway that controls the cholesterol content of membranes, cells and blood. Proc Natl Acad Sci USA 1999;96:11041-11048.
38.
Sion B, Grizard G, Boucher D: Quantitative analysis of desmosterol, cholesterol and cholesterol sulfate in semen by high-performance liquid chromatography. J Chromatogr A 2001;935:259-265.
39.
Rinn JL, Rozowsky JS, Laurenzi IJ, Petersen PH, Zou K, Zhong W, Gerstein M, Snyder M: Major molecular differences between mammalian sexes are involved in drug metabolism and renal function. Dev Cell 2004;6:791-800.
40.
Lindenthal B, Holleran AL, Aldaghlas TA, Ruan B, Schroepfer GJ Jr, Wilson WK, Kelleher JK: Progestins block cholesterol synthesis to produce meiosis-activating sterols. FASEB J 2001;15:775-784.
41.
Clayton PT: Disorders of cholesterol biosynthesis. Arch Dis Child 1998;78:185-189.
42.
Wechsler A, Brafman A, Shafir M, Heverin M, Gottlieb H, Damari G, Gozlan-Kelner S, Spivak I, Moshkin O, Fridman E, Becker Y, Skaliter R, Einat P, Faerman A, Bjorkhem I, Feinstein E: Generation of viable cholesterol-free mice. Science 2003;302:2087.
43.
Vainio S, Jansen M, Koivusalo M, Rog T, Karttunen M, Vattulainen I, Ikonen E: Significance of sterol structural specificity. Desmosterol cannot replace cholesterol in lipid rafts. J Biol Chem 2006;281:348-355.
44.
Yang C, McDonald JG, Patel A, Zhang Y, Umetani M, Xu F, Westover EJ, Covey DF, Mangelsdorf DJ, Cohen JC, Hobbs HH: Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem 2006;281:27816-27826.
45.
Rodriguez-Acebes S, de la CP, Fernandez-Hernando C, Ferruelo AJ, Lasuncion MA, Rawson RB, Martinez-Botas J, Gomez-Coronado D: Desmosterol can replace cholesterol in sustaining cell proliferation and regulating the SREBP pathway in a sterol-Δ24-reductase-deficient cell line. Biochem J 2009;420:305-315.
46.
Greeve I, Hermans-Borgmeyer I, Brellinger C, Kasper D, Gomez-Isla T, Behl C, Levkau B, Nitsch RM: The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J Neurosci 2000;20:7345-7352.
47.
Iivonen S, Hiltunen M, Alafuzoff I, Mannermaa A, Kerokoski P, Puolivali J, Salminen A, Helisalmi S, Soininen H: Seladin-1 transcription is linked to neuronal degeneration in Alzheimer's disease. Neuroscience 2002;113:301-310.
48.
Wu C, Miloslavskaya I, Demontis S, Maestro R, Galaktionov K: Regulation of cellular response to oncogenic and oxidative stress by seladin-1. Nature 2004;432:640-645.
49.
Kuehnle K, Crameri A, Kalin RE, Luciani P, Benvenuti S, Peri A, Ratti F, Rodolfo M, Kulic L, Heppner FL, Nitsch RM, Mohajeri MH: Prosurvival effect of DHCR24/seladin-1 in acute and chronic responses to oxidative stress. Mol Cell Biol 2008;28:539-550.
50.
Crameri A, Biondi E, Kuehnle K, Lutjohann D, Thelen KM, Perga S, Dotti CG, Nitsch RM, Ledesma MD, Mohajeri MH: The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Aβ generation in vivo. EMBO J 2006;25:432-443.
51.
Wang N, Yvan-Charvet L, Lutjohann D, Mulder M, Vanmierlo T, Kim TW, Tall AR: ATP-binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain. FASEB J 2008;22:1073-1082.
52.
Jiang XS, Wassif CA, Backlund PS, Song L, Holtzclaw LA, Li Z, Yergey AL, Porter FD: Activation of Rho GTPases in Smith-Lemli-Opitz syndrome: pathophysiological and clinical implications. Hum Mol Genet 2010;19:1347-1357.
53.
Korade Z, Kenworthy AK, Mirnics K: Molecular consequences of altered neuronal cholesterol biosynthesis. J Neurosci Res 2009;87:866-875.
54.
FitzPatrick DR, Keeling JW, Evans MJ, Kan AE, Bell JE, Porteous MEM, Mills K, Winter RM, Clayton PT: Clinical phenotype of desmosterolosis. Am J Med Genet 1998;75:145-152.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.